Yunnan Zhongke Longjin Biological Technology

Yunnan Zhongke Longjin Biological Technology is a Chinese biotechnology company dedicated to the discovery and development of innovative drugs based on animal venom peptides. Established as a joint venture between Kunming Longjin Pharmaceutical and the Kunming Institute of Zoology of the Chinese Academy of Sciences, the company operates at the intersection of natural product research and recombinant protein engineering. Its primary focus is on addressing unmet needs in cardiovascular and neurological medicine, particularly in the treatment of ischemic stroke and chronic pain. The company's lead candidate, ZKLJ-02, is a recombinant thrombin-like enzyme currently in clinical development. By leveraging the extensive venom library of the Chinese Academy of Sciences, the firm aims to provide high-purity, standardized biological alternatives to traditional animal-derived extracts.